TMSB4X: A novel prognostic marker for non-small cell lung cancer.
| Autor: | Yang Z; Guangdong Provincial Key Laboratory of Tumor Interventional Diagnosis and Treatment, Zhuhai People's Hospital (Zhuhai Hospital Affiliated with Jinan University), Zhuhai, Guangdong, China.; The Second Affiliated Hospital of Zunyi Medical University, Zun Yi, Gui Zhou, China., Luo J; Affiliated Hospital of Zunyi Medical University, Zun Yi, Gui Zhou, China., Zhang M; Zunyi Medical and Pharmaceutical College, Zun Yi, Gui Zhou, China., Zhan M; Guangdong Provincial Key Laboratory of Tumor Interventional Diagnosis and Treatment, Zhuhai People's Hospital (Zhuhai Hospital Affiliated with Jinan University), Zhuhai, Guangdong, China., Bai Y; The Second Affiliated Hospital of Zunyi Medical University, Zun Yi, Gui Zhou, China., Yang Y; The Second Affiliated Hospital of Zunyi Medical University, Zun Yi, Gui Zhou, China., Wang W; Department of Pulmonary and Critical Care Medicine, Zhuhai People's Hospital (Zhuhai Hospital Affiliated with Jinan University), Zhuhai, Guangdong, China., Lu L; Guangdong Provincial Key Laboratory of Tumor Interventional Diagnosis and Treatment, Zhuhai People's Hospital (Zhuhai Hospital Affiliated with Jinan University), Zhuhai, Guangdong, China. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Heliyon [Heliyon] 2023 Nov 04; Vol. 9 (11), pp. e21505. Date of Electronic Publication: 2023 Nov 04 (Print Publication: 2023). |
| DOI: | 10.1016/j.heliyon.2023.e21505 |
| Abstrakt: | Non-small cell lung cancer (NSCLC), as the main type of lung cancer, has a long history of high incidence and mortality. Despite the continuous updates to the American Joint Committee on Cancer (AJCC) staging system, which adapt to evolving treatment modalities and diagnostic advancements, it is evident that patients at the same stage exhibit varying prognoses. The heterogeneity of tumors underscores the need for molecular diagnostics to assume a pivotal role in tumor staging and patient stratification. In our investigation, we meticulously analyzed the data of the Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) database, incorporating clinical patients and scrutinizing pathological specimens. Through this comprehensive approach, we established a correlation between the expression of the Thymosin beta 4 X-linked (TMSB4X) gene and poorer disease-free survival (DFS) and overall survival (OS) post-surgery. Compared to the TMSB4X positive expression group, patients in the negative expression group had a better prognosis, with longer DFS (median disease-free survival (median DFS): 16.2 months vs. 11.3 months, P = 0.032) and OS (median overall survival (mOS): 29.8 months vs. 18.5 months, P = 0.033). Furthermore, our findings suggest that TMSB4X may facilitate immune evasion in non-small cell lung cancer cells by influencing the activation of infiltrating dendritic cells (DCs) in tumor infiltrating immune cells (TIICs) (R = 0.27, P = 4.8E+08). In summary, TMSB4X emerges as an unfavorable prognostic factor for NSCLC, potentially modulating the tumor immune microenvironment through its regulatory impact on dendritic cell function, thus facilitating tumor immune escape. Competing Interests: Ze Yang, Jihang Luo, Mengmei Zhang, Meixiao Zhan, Yuju Bai, Yi Yang, Wei Wang and Ligong Lu declare that they have no conflict of interest.All authors declare that we have no financial and personal relationships with other people or organizations that can inappropriately influence our work, there is no professional or other personal interest of any nature or kind in any product, service and/or company that could be construed as influencing the position presented in, or the review of, the manuscript entitled. (© 2023 The Authors. Published by Elsevier Ltd.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|